Drugs / DCIKKb
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04335890 | Sep 2020 → Sep 2022 | uveal melanoma | Hasumi International Research Foundation | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DCIKKb | “DCIKKb = autologous, monocyte-derived DC that are matured with the standard cocktail” NCT04335890 ↗ |
| Modality | Cell therapy | “3rd generation personalized IKKβ-matured RNA-transfected dendritic cell (DC) vaccine” PMID 35185883 ↗ Feb 2022 |
| Route | Intravenous | “Intravenous infusion of 7.5 to 30 mio DCIKKb” NCT04335890 ↗ |